Physician
General Surgery
Dr. Brian H. Carr, DDS
|
|
Give Review
Brian Carr works in the field of General Surgery. He graduated from Imperial College London School of Medicine. Brian Carr is a published physician. He published 76 publications, including: 'Erratum to: Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis.'
Publications
- Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis.
- Erratum to: Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis.
- Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients.
- Guest editorial: platelets and cancer.
- Modulation of Doxorubicin Mediated Growth Inhibition of Hepatocellular Carcinoma Cells by Platelet Lysates.
- Low alpha-fetoprotein HCC and the role of GGTP.
- A Systematic Review of Randomized Controlled Trials Testing the Efficacy of Psychosocial Interventions for Gastrointestinal Cancers.
- Macro- and Micro-environmental Factors in Clinical Hepatocellular Cancer.
- Features of massive hepatocellular carcinomas.
- Significance of platelet and AFP levels and liver function parameters for HCC size and survival.
- Hepatocellular Carcinoma Size: Platelets, γ-Glutamyl Transpeptidase, and Alkaline Phosphatase.
- Thrombocytosis and hepatocellular carcinoma.
- Phenotypic Categorization and Profiles of Small and Large Hepatocellular Carcinomas.
- Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery.
- Prospective randomized trial of hepatic artery chemotherapy with Cisplatin and Doxorubicin, with or without lipiodol in the treatment of advanced stage hepatocellular ...
- c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition.
- Peripheral Blood Lymphocyte Depletion After Hepatic Arterial (90)Yttrium Microsphere Therapy for Hepatocellular Carcinoma.
- Small HCCs Identified by Screening.
- Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma.
- Differential Effects of Vitamin K1 on AFP and DCP Levels in Patients with Unresectable HCC and in HCC Cell Lines.
- Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
- HCC in older patients.
- Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients.
- Pain at presentation and survival in hepatocellular carcinoma.
- Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in sorafenib-induced cytoskeletal rearrangement in hepatoma cells.
- Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.
- Cancer-related symptom clusters, eosinophils, and survival in hepatobiliary cancer: an exploratory study.
- Network-based analysis of survival for unresectable hepatocellular carcinoma.
- Regional hepatic therapy for cancer.
- Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort...
- Welcome to the journal of Gastrointestinal Cancer, 2010.
- Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study.
- Involvement of ATM-mediated Chk1/2 and JNK kinase signaling activation in HKH40A-induced cell growth inhibition.
- Hepatobiliary effects of 90yttrium microsphere therapy for unresectable hepatocellular carcinoma.
- Integrin alpha5-induced EGFR activation by prothrombin triggers hepatocyte apoptosis via the JNK signaling pathway.
- Measuring post-traumatic growth in people diagnosed with hepatobiliary cancer: directions for future research.
- Chemo-embolization for unresectable hepatocellular carcinoma with different sizes of embolization particles.
- Gender-based outcomes differences in unresectable hepatocellular carcinoma.
- Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.
- Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience.
- Grb2-associated binder-1 plays a central role in the hepatocyte growth factor enhancement of hepatoma growth inhibition by K vitamin analog compound 5.
- Posttraumatic growth, immunity and survival in patients with hepatoma.
- Depression, immunity, and survival in patients with hepatobiliary carcinoma.
- Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the ...
- Preliminary results of an individually tailored psychosocial intervention for patients with advanced hepatobiliary carcinoma.
- H32, a non-quinone sulfone analog of vitamin K3, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating ERK.
- Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in ...
- Phosphorylation regulates Myc expression via prolonged activation of the mitogen-activated protein kinase pathway.
- PM-20, a novel inhibitor of Cdc25A, induces extracellular signal-regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo.
- Outcome of 1000 liver cancer patients evaluated at the UPMC Liver Cancer Center.
- Sexual functioning in patients with hepatocellular carcinoma.
- Cdc25A and ERK interaction: EGFR-independent ERK activation by a protein phosphatase Cdc25A inhibitor, compound 5.
- Hepatocyte growth factor enhances protein phosphatase Cdc25A inhibitor compound 5-induced hepatoma cell growth inhibition via Akt-mediated MAPK pathway.
- Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy.
- Novel hydroxyl naphthoquinones with potent Cdc25 antagonizing and growth inhibitory properties.
- Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities.
- Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis.
- The effects of hepatic artery chemotherapy on viral hepatitis in patients with hepatocellular carcinoma.
- Hepatocellular carcinoma: current management and future trends.
- Yttrium-90 microspheres for the treatment of hepatocellular carcinoma.
- Characteristics of hepatocellular carcinoma in a high arsenicism area in Taiwan: a case-control study.
- NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.
- Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients.
- JS-K, a novel non-ionic diazeniumdiolate derivative, inhibits Hep 3B hepatoma cell growth and induces c-Jun phosphorylation via multiple MAP kinase pathways.
- Binding and inhibition of Cdc25 phosphatases by vitamin K analogues.
- To transplant, or not to transplant?
- Persistent ERK phosphorylation negatively regulates cAMP response element-binding protein (CREB) activity via recruitment of CREB-binding protein to pp90RSK.
- Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma.
- K vitamins, PTP antagonism, and cell growth arrest.
- Yttrium-90 microspheres: radiation therapy for unresectable liver cancer.
- Transient and sustained ERK phosphorylation and nuclear translocation in growth control.
- Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase.
- EGFR-independent activation of ERK1/2 mediates growth inhibition by a PTPase antagonizing K-vitamin analog.
- Hepatocellular carcinoma in noncirrhotic liver: CT, clinical, and pathologic findings in 39 U.S. residents.
- Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.
Procedures Preformed
- Clear Dental Braces
- In-Office Teeth Whitening
Doctors Specialties
- Dentistry
- General Surgery
Accepted Insurances
- Dental DPPO
- Ameritas PPO
- DHA Premier
- Regional Preferred Dental PPO
- Regional Traditional Dental
- Delta Dental PPO
- Delta Dental Premier
- Dental Network of America DPPO
- Dental PPO
- DentalGuard Preferred
- MetLife PDP
- Advantage Plus PPO
- National Fee-for-Service
Education
-
University of Wisconsin -
Imperial College London School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Juichih Hsu, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hien Q. Nguyen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Allen Davies, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth P. Lowe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher W. Koterwas, DDS |
|
|
Dr. Prakash Vaidy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael B. Lipman, DDS |
|
|
Dr. Charles V. Pasqualini Jr., DMD |
|
|
Dr. Amy M. Mikula, DDS |
|
|
Dr. Paul B. Lavine, DDS |
|
|
Dr. Shouleh Motamedi, DDS |
|
|
Dr. John E. Phillips III, DMD |